Johnson & Johnson $JNJ Shares Sold by Lokken Investment Group LLC

Lokken Investment Group LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 8,854 shares of the company’s stock after selling 82 shares during the period. Lokken Investment Group LLC’s holdings in Johnson & Johnson were worth $1,353,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Armstrong Fleming & Moore Inc increased its position in Johnson & Johnson by 221.5% in the 2nd quarter. Armstrong Fleming & Moore Inc now owns 12,588 shares of the company’s stock valued at $1,923,000 after acquiring an additional 8,673 shares during the period. Fulton Breakefield Broenniman LLC increased its position in Johnson & Johnson by 2.7% in the 2nd quarter. Fulton Breakefield Broenniman LLC now owns 21,860 shares of the company’s stock valued at $3,339,000 after acquiring an additional 576 shares during the period. Columbus Macro LLC increased its position in Johnson & Johnson by 4.5% in the 2nd quarter. Columbus Macro LLC now owns 35,415 shares of the company’s stock valued at $5,410,000 after acquiring an additional 1,532 shares during the period. Values Added Financial LLC increased its position in Johnson & Johnson by 11.8% in the 2nd quarter. Values Added Financial LLC now owns 1,696 shares of the company’s stock valued at $259,000 after acquiring an additional 179 shares during the period. Finally, Cohen Investment Advisors LLC increased its position in Johnson & Johnson by 11.1% in the 2nd quarter. Cohen Investment Advisors LLC now owns 24,117 shares of the company’s stock valued at $3,684,000 after acquiring an additional 2,418 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $190.66 on Friday. The business’s 50 day simple moving average is $178.48 and its 200-day simple moving average is $163.76. The firm has a market capitalization of $459.16 billion, a price-to-earnings ratio of 20.39, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $192.10.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson’s payout ratio is 55.61%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on JNJ. The Goldman Sachs Group boosted their price target on Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a research report on Thursday. Wells Fargo & Company set a $212.00 target price on Johnson & Johnson and gave the stock an “overweight” rating in a research report on Friday, October 3rd. Guggenheim upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Piper Sandler reiterated an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Finally, Citigroup boosted their target price on Johnson & Johnson from $200.00 to $213.00 and gave the stock a “buy” rating in a research report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $192.94.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.